Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA"

J Thorac Oncol. 2023 Sep;18(9):e102-e103. doi: 10.1016/j.jtho.2023.05.022.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Ipilimumab / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Nivolumab / therapeutic use

Substances

  • Ipilimumab
  • Nivolumab